News

9-valent, quadrivalent HPV vaccines have comparable safety


 

FROM PEDIATRICS

References

The 9-valent human papillomavirus vaccine was well tolerated in 16-26 year olds and had a safety profile comparable to that of the quadrivalent vaccine, according to an analysis of seven phase III trials.

“The demonstrated efficacy and favorable safety profile of the 9vHPV vaccine support widespread vaccination programs,” reported Dr. Edson D. Moreira Jr. and his associates in Pediatrics.

Vaccines were given in a three-dose regimen: 15,776 male and female patients received at least one dose of the 9-valent vaccine and 7,391 control subjects received at least one dose of the quadrivalent vaccine.

Frequencies of vaccine-related systemic adverse events such as headache and pyrexia were “generally similar” between the two vaccine groups, the investigators reported.

Compared with the quadrivalent vaccine, the 9-valent vaccine was associated with significantly more frequent adverse events at the injection site, including pain (84% vs. 90%), swelling (29% vs. 40%), and erythema (34% vs. 26%). Most of these reactions in both groups were mild to moderate in intensity, however.

Discontinuations and vaccine-related serious adverse events in the 9-valent vaccine group were rare (0.1% and less than 0.1%, respectively).

Read the full study here (doi:10.1542/peds.2015-4387).

acruz@frontlinemedcom.com

Recommended Reading

Vaccinations in certain combinations may slightly increase febrile seizure risk
MDedge Family Medicine
FDA approves first cholera vaccine for travelers
MDedge Family Medicine
ACIP recommends MenACWY vaccine for HIV-infected persons 2 months and older
MDedge Family Medicine
ACIP votes to scrap LAIV vaccine for 2016-2017 influenza season
MDedge Family Medicine
ACIP hints at move from three-dose to two-dose HPV vaccination schedule for youth
MDedge Family Medicine
Zika vaccine development to get underway
MDedge Family Medicine
Novel vaccine scores better hepatitis B seroprotection in type 2 diabetes
MDedge Family Medicine
Appreciate family cognitive style when discussing vaccines
MDedge Family Medicine
Malaria vaccine disappoints in phase II trial
MDedge Family Medicine
Incidence of HPV-associated cancers on the rise
MDedge Family Medicine